Skip to main content
. 2021 Feb 19;11:555996. doi: 10.3389/fimmu.2020.555996

Figure 1.

Figure 1

Anti-CD70 antibody (FR70) treatment induced long-term acceptance of mouse cardiac grafts. (A) FR70 (500 µg) was intraperitoneally (i.p.) injected into C3H recipient mice immediately after heterotopic cardiac transplantation, and in the following 5 days, three additional half-dose (250 µg, i.p.) FR70 injections were performed. (B) The graft survival data are presented in detail. C3H recipients that underwent transplantation of a heart from B6 mice were either not treated or treated with FR70 (n = 18 mice for not treated group, n = 25 mice for treated group, mean ± SEM, pooled from five independent experiments). The mean survival time (MST) is shown in Table 1 . A statistical evaluation of the graft survival was performed using Kaplan–Meier curves and compared using log-rank tests, ****p < 0.0001. (C) Histologic studies of harvested cardiac grafts were performed with hematoxylin–eosin (HE) staining. Syngeneic B6 heart (Syngeneic), isotype control-treated B6 cardiac allograft (Allo) and FR70-treated B6 cardiac allograft (Allo + FR70) on POD7 are shown (n = 3 mice/group, scale bars: 200 µm).